Press Release
Dolly Varden Silver Wolf Vein is Now a Priority as Silver Price Hits 14 Year High
The mineralization in drill hole DV25-446 includes native silver and is consistent with the robust style of mineralization with a significant increase in associated gold and base metal values. Additional drilling at Wolf is being prioritized for the remainder of the season
Vancouver, BC – September 4, 2025 – Global Stocks News – Sponsored content disseminated on behalf of Dolly Varden Silver. On September 2, 2025 Dolly Varden Silver (TSXV: DV) (NYSE American: DVS) (FSE: DVQ) announced that backfill directional drilling at the Wolf Vein in hole DV25-446 has intersected 1,422 g/t silver over 21.70 meters, including 10,700 g/t silver over 1.00 meter.

The ongoing success at the Wolf Vein is a lesson in the importance of hiring and empowering young geological talent. DV inherited archival drill data that went back to 1910. Four years ago, a new hire, Amanda Bennett, reviewed and analysed the old data.
Bennett zeroed in on the Wolf Vein as an area of interest. Dolly Varden’s VP of Exploration Rob van Egmond looked at her model, and said, “Let’s give it a try”.
“Back in 2021, we drilled the downward extension from the Wolf Mine and found a continuation of the system,” Bennett told Global Stocks News (GSN). “We’ve followed it at depth, extending it well over 1,100 meters. The Wolf Vein has exceeded my expectations.”
“These high-grade silver results over wide intervals suggest excellent continuity at the Wolf Vein,” stated Shawn Khunkhun, CEO of Dolly Varden Silver, in the August 2, 2025 press release. “The mineralization in drill hole DV25-446 includes native silver and is consistent with the robust style of mineralization with a significant increase in associated gold and base metal values. Additional drilling at Wolf is being prioritized for the remainder of the season.”
“The gold and base metal grades are getting stronger as we go deeper at the Wolf Vein,” van Egmond confirmed to GSN. “With gold at an all-time high, that is a positive development. The lead and zinc numbers also impact the metallurgy. The lead helps with the silver recoveries.”

The existing road to the Wolf Vein is currently not accessible. It is more efficient to use a helicopter for crew change and resupply.
“There’s no camp there,” confirmed Bennett. “It’s just a drill site. Every 12 hours, the helicopter delivers the drill crew, and the other crew rotates out. We have two project managers spelling each other off, who supervise the drillers.”
Leasing a helicopter is not cheap, but van Egmond told GSN that new technologies available in remote locations are providing savings.
“We now have a reliable satellite internet connection,” van Egmond told GSN, “which enables both the drilling crew and geologists to communicate with us in real time. They log the data onto a tablet and download it to an off-site server.”
“The drills also have satellite connection now,” continued van Egmond. “So the drillers can send pictures of the core in real time.”

Dolly Varden is using directional drilling technology to precisely target areas for step-out and infill work at both Wolf and Homestake Silver. Drillhole DV25-446 is a deflection hole (daughter hole) off the initial “mother” hole. The vein intercept in DV25-446 is approximately 105 meters up plunge (in-fill) from the 2024 step out DV24-421.
The directional drilling has allowed DV to decrease total meters drilled by utilizing the same mother hole numerous times.
The 55,000-meter 2025 summer drill campaign is estimated using the total length of each drill hole as if each hole started from surface. Since the total meterage estimate includes those “re-drilled” mother hole lengths, actual meters of new core will be in the order of 41,000 meters, thus achieving the same number of mineralized intercepts while drilling significantly fewer meters at Wolf and Homestake Silver.
“Mining companies use directional drilling when they want to reduce the total number of drilled meters for a multi-target drilling program,” confirms DV drill contractor Aziwell. “It is highly efficient and precise.”
Ten years ago, Dolly Varden was a “silver pure play”, which is quite rare. Seventy percent of global silver production comes from lead, zinc and gold mines, where silver is produced as a by-product.
In the last few years, Dolly Varden has started hitting significant gold intercepts. For example, in February 2024, a step-out drill program at Homestake Ridge intersected a new gold-rich zone: HR23-389: 79.49 g/t gold over 12.45 meters.
DV’s metal inventory value is now approximately a 50/50 split between silver and gold.
The rising price of gold has a double benefit for Dolly Varden: 1. It increases the value of the gold-in-the-ground inventory, 2. If the silver-gold ratio returns to its historical norm, it may boost the price of silver.
“The Silver price jumped above the USD 40 per troy ounce mark for the first time in 14 years at the beginning of the week, buoyed by the rise in the Gold price,” Commerzbank’s commodity analyst Carsten Fritsch notes.
On April 15, 2025 – DV Announced Common Shares Have Been Approved for Listing on the NYSE
Since then, Dolly Varden has significantly increased its land package:
May 5, 2025 – DV Announces Agreement to Quadruple Tenure Area in the Golden Triangle by Acquiring Hecla Mining Company’s Adjacent Kinskuch Property
May 8, 2025 – DV Acquires High-Grade Silver Porter Project in Golden Triangle
“Our progress in 2025 is the culmination of five years of hard work by our team,” Khunkhun told GSN. “In that time span, we’ve gone from two past-producing historical mines to five, we’ve drilled 141,000 meters with consistent high-grade silver and gold hits, our land package has gone from 7,000 hectares to 100,000 (+1,400%), and our market capitalisation has moved from $20 million to $460 million (+2,200%).
As the drilling season closes out, five diamond drills are working on the Kitsault Valley and Big Bulk Projects. Focus has been on step-out and infill drilling of the Wolf Vein and Homestake Silver deposits, as well as exploration drilling of the copper-gold porphyry system at Big Bulk and several other targets in the Kitsault Valley. More results will be released as they are received and incorporated into the company’s models.
Rob van Egmond, P.Geo., Vice-President Exploration for Dolly Varden Silver, the “Qualified Person” as defined by NI43-101, has reviewed, validated and approved the scientific and technical information contained in this GSN release.
Disclaimer: Dolly Varden Silver paid GSN $1,750 for the research, creation and dissemination of this content.
Contact: guy.bennett@globalstocksnews.com
Full Disclaimer: Global Stocks News (GSN) researches and fact-checks diligently, but we cannot ensure our publications are free from error. Investing in publicly traded stocks is speculative and carries a high degree of risk. GSN makes no recommendation to purchase any individual stock. When compensation has been paid to GSN, the amount and nature of the compensation will be disclosed clearly. GSN publications may contain forward-looking statements such as “project,” “anticipate,” “expect,” which are based on reasonable expectations, but these statements are imperfect predictors of future events.
Media Contact
Organization: Global Stocks News
Contact Person: guy.bennett@globalstocksnews.com
Website: https://www.globalstocksnews.com
Email: Send Email
Country: Canada
Release id: 33448
The post Dolly Varden Silver Wolf Vein is Now a Priority as Silver Price Hits 14 Year High appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).
MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.
The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.
If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.
On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.
About AD Indication
MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry
- Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CGTN: President Xi Jinping: China, U.S. should work for good of both countries, world
Following a face-to-face meeting between Chinese President Xi Jinping and U.S. President Donald Trump, CGTN published an article highlighting how head-of-state diplomacy provides strategic guidance for bilateral ties and how China and the United States can work together for the good of both countries and the world as a whole.
Chinese President Xi Jinping said on Thursday that China and the United States can jointly shoulder responsibility as major countries, and work together to accomplish more great and concrete things for the good of their two countries and the whole world.
President Xi made the remarks during a meeting with U.S. President Donald Trump after he landed in Busan, the Republic of Korea (ROK), ahead of the 32nd APEC Economic Leaders’ Meeting in Gyeongju and his state visit to the ROK.
The in-person talks came after three phone conversations and several exchanges of letters between the two presidents since Trump was re-elected.
President Xi said the latest round of China-U.S. consultation in Kuala Lumpur, Malaysia, where the two economic and trade teams reached consensus on solving various issues, has provided the necessary conditions for the meeting.
“Dialogue is better than confrontation,” he said. China and the U.S. should maintain communication through various channels and at various levels to enhance mutual understanding, Xi added.
The Chinese and U.S. presidents agreed to maintain interactions on a regular basis. Trump said he looked forward to visiting China early next year, and invited President Xi to visit the United States.
‘Business should remain anchor for ties’
The relationship between China and the U.S. is widely viewed as the most consequential bilateral relationship in the world, since the two nations, combined, are home to over 40 percent of the global GDP, according to a survey by the Chicago Council on Global Affairs, a U.S. think tank.
An annual membership survey from the U.S.-China Business Council, released in July, found that more than 80 percent of American companies doing business in China were profitable last year and said they will remain committed to pursuing opportunities in China over the long term.
Statistics from the United Nations show that the volume of trade in goods between China and the U.S. in 2024 reached $688.28 billion, which was 275 times that of 1979, when diplomatic relations were established. In addition, Chinese statistics ranked the U.S. as its second-largest trade partner in services in 2023 while U.S. data listed China as its fifth-largest services export market.
The business relationship should continue to serve as the anchor and driving force for China-U.S. relations, not a stumbling block or a point of friction, said Xi during Thursday’s talks.
“The two sides should think big and recognize the long-term benefit of cooperation, and must not fall into a vicious cycle of mutual retaliation,” he said.
Xi called on the two countries’ economic and trade teams to continue talks in the spirit of equality, mutual respect and mutual benefit, and continuously shorten the list of problems and lengthen the list of cooperation.
According to a recent CGTN poll, 87 percent of respondents believe China-U.S. economic and trade relations are fundamentally mutually beneficial, and 84.4 percent think closer China-U.S. economic and trade cooperation not only benefits both economies, but also provides a key safeguard for the stability of global industrial and supply chains.
‘China, U.S. should be partners, friends’
During Thursday’s meeting, President Xi emphasized that China’s development and revitalization goes hand in hand with President Trump’s vision to “Make America Great Again.”
China and the U.S. are fully able to help each other succeed and prosper together, Xi said.
The findings of the survey by the the Chicago Council on Global Affairs, released on Tuesday, show that 53 percent of Americans now say the U.S. should undertake friendly cooperation and engagement with China, up from 40 percent in 2024.
China and the U.S. should be partners and friends, Xi said. “That is what history has taught us and what reality needs.”
Given different national conditions, the two countries do not always see eye to eye with each other and it is normal for the two leading economies of the world to have frictions now and then, he said.
In the face of winds, waves and challenges, President Xi said, the two heads of state should stay on the right course, navigate through the complex landscape and ensure the steady sailing forward of the giant ship of China-U.S. relations.
Trump said the U.S. and China have always had a “fantastic” relationship and it will be even better. “We will make both China and the U.S. even better,” he said.
China is the biggest partner of the United States, Trump said. “Together, our two countries can get many great things done for the world and have many years of success.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
PrairieVault Exchange Rolls Out Embedded Training Modules for Institutional Users
PrairieVault Exchange introduces embedded training modules within its platform, offering institutions interactive, scenario-based education to streamline onboarding, reinforce compliance, and support operational readiness directly in the trading environment.
United States, 30th Oct 2025, Grand Newswire – PrairieVault Exchange announced the official launch of its platform-embedded training modules, a new initiative designed to provide hands-on, scenario-based education directly within its trading interface. This development aims to accelerate the onboarding of enterprise clients and elevate operational standards across institutional desks.
Enhancing Institutional Readiness through Embedded Education
Unlike traditional learning systems that rely on off-platform resources, the new PrairieVault initiative allows institutions to train directly within the live platform—leveraging context-aware modules that simulate real trading workflows, permission delegation, risk controls, and data handling protocols.
These modules are built around key areas of institutional operation:
Role-based access control (RBAC) walkthroughs
Sub-account permissions and supervision logic
Risk scenario simulations using behavioral models
Audit trail management and data responsibility practices
Bridging Education and Execution
The rollout reflects PrairieVault Exchange’s broader commitment to security-by-design and learning-in-context, especially as it attracts a growing number of asset managers, proprietary trading firms, and fintech service providers. Rather than requiring teams to read manuals or attend webinars, the embedded modules allow “learn by doing” via guided, in-environment tasks.
“Platform-integrated training is a critical step in helping institutional clients operationalize faster and safer,” said Dominic Rahm, Head of Developer Infrastructure at PrairieVault Exchange. “From compliance walkthroughs to live feature trials, institutions can now align training and execution on a unified surface.”
Strategic Fit for Scaling Institutions
PrairieVault Exchange has seen increased demand from regulated entities and enterprise users that prioritize structured onboarding, internal audit compliance, and workflow standardization. The new module system offers team-specific dashboards, progress tracking, and administrative insights into usage trends—allowing institutions to monitor internal readiness before full deployment.
The embedded training framework is available immediately to verified institutional accounts and is fully integrated with PrairieVault’s Smart Account Framework and Modular SDK Layer, ensuring consistent governance and user segmentation.
About PrairieVault Exchange
PrairieVault Exchange is a technology-first trading infrastructure provider focused on institutional-grade performance, risk-aware systems, and modular deployment. Its platform supports secure multi-account structures, behavioral analytics, and developer integration—delivering the precision needed for today’s digital financial ecosystems.
For more information about PrairieVault Exchange, visit one of the following sources:
https://www.prairie-vault.info
https://www.prairievault.review
https://www.prairievault-reviews.com
https://www.prairievault-overview.com
https://www.prairievault.exchange
Disclaimer:
This press release is for informational purposes only and does not constitute financial, investment, or legal advice. PrairieVault Exchange does not make any guarantees regarding future performance or outcomes related to the use of its products or services. Institutions are encouraged to evaluate product suitability based on their own operational requirements and risk frameworks.
Media Contact
Organization: PrairieVault
Contact
Person: Elizabeth Chambers
Website:
https://prairievault.com/
Email:
service@prairievault.com
Country:United States
The post PrairieVault Exchange Rolls Out Embedded Training Modules for Institutional Users
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release7 days ago
Emdoor Digital Shines at Hong Kong Electronics Fair, Ushering in a New Era of Intelligence with All-Scenario AI Terminal Devices
-
Press Release5 days ago
Breaking Barriers for Entrepreneurs: Why Nicholas Sgalitzer Believes NexTech Labs is the Missing Link for Startups
-
Press Release5 days ago
10 Questions to Ask Before Fertility Treatment, with Project Life
-
Press Release1 week ago
DJ Service Recruits Professional DJs Across South Africa
-
Press Release5 days ago
Premier Glow Lights Up the Party Scene with Fresh LED Novelties and Night-Golf Solutions
-
Press Release23 hours ago
ReyVend Unveils Next-Generation AI Vending and Smart Cooler Platform, Pioneering the Future of Automated Retail
-
Press Release5 days ago
Lykyn Smart Mushroom Grow Kit The Easiest Way to Grow Gourmet Mushrooms at Home
-
Press Release3 days ago
Ustyle Magazine Redefines Digital Media with Fashion Beauty and Lifestyle Trends
